Abstract
RET gene alterations as disease-causative mutations have been demonstrated in five different disease entities: Hirschsprung's disease (HD); papillary thyroid carcinoma; and three types of inherited cancer syndromes: multiple endocrine neoplasia (MEN) 2A, MEN 213, and familial medullary thyroid carcinoma. RET is expressed during embryogenesis in a temporally and spatially regulated manner, and plays an important role in the normal development of a variety of cell lineages, particularly in the establishment of the enteric nervous system.RET mutations observed in patients with HD are scattered along the gene without any hot spots, and possess a loss-of-function effect.RET mutations are detected with a higher incidence among familial cases (50%) than sporadic cases (15%–20%), and are more closely associated with long-segment HD than short-segment disease. In contrast to HD mutations, missense mutations observed in MEN 2 syndromes occur at specific codons, and gene rearrangements are characteristic in papillary thyroid carcinoma. Both missense mutations and gene rearrangements act in a dominant fashion, and cause constitutive phosphorylation on the tyrosine of RET and highly enhance RET kinase activity, leading to transforming or oncogenic activity.
Similar content being viewed by others
References
Takahashi M, Ritz J, Cooper G (1985) Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42: 581–588
Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H (1988) Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3: 571–578
Takahashi M, Buma Y, Hiai H (1989) Isolation of ret protooncogene cDNA with an amino-terminal signal sequence. Oncogene 4: 805–806
Tahira T, Ishizaka Y, Itoh F, Sugimura T, Nagao M (1990) Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. Oncogene 5: 97–102
Ceccherini I, Bocciardi R, Luo Y, Pasini B, Hofstra R, Takahashi M, Romeo G (1993) Exon structure and flanking intronic sequences of the human RET proto-oncogene. Biochem Biophys Res Commun 196: 1288–1295
Kwok J, Gardner E, Warner J, Ponder B, Mulligan L (1993) Structural analysis of the human ret proto-oncogene using exon trapping. Oncogene 8: 2575–2582
Ishizaka Y, Itoh F, Tahira T, Ikeda I, Sugimura T, Tucker J, Fertitta A, Carrano AV, Nagao M (1989) Human ret protooncogene mapped to chromosome 10g11.2. Oncogene 4: 1519–1521
Schneider R (1992) The human protooncogene ret: a communicative cadherin? TIBS 17: 468–469
Jing S (1996) Cell 85: 1113–1124
Trupp M, Arenas E, Fainzilber M, Nilsson A, Sieber B, Grigoriou M, Kilkenny C, Salazar-Grueso E, Pachnis V, Arumae U (1996) Functional receptor for GDNF encoded by the c-ret protooncogene. Nature 381: 785–789
Durbec P, Marcos-Gutierrez C, Kilkenny C, Grigoriou M, Wartiowaara K, Suvanto P, Smith D, Ponder B, Costantini F, Saarma M (1996) GDNF signalling through the ret receptor tyrosine kinase. Nature 381: 789–793
Treanor J, Goodman L, de Sauvage F, Stone D, Poulson K, Beck C, Gray C, Armanini M, Pollock R, Hefti F (1996) Characterization of a multicomponent receptor for GDNF. Nature 382: 80–83
Lin L, Doherty D, Lile J, Bektesh S, Collins F (1993) GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130–1132
Henderson C, Phillips H, Pollock R, Davies A, Lemeulle C, Armanini M, Simpson L, Moffet B, Vandlen R, Koliatsos V (1994) GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266: 1062–1064
Tomac A, Lindqvist E, Lin L, Ogren S, Young D, Hoffer B, Olson L (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373: 335–339
Beck K, Valverde J, Alexi T, Poulsen K, Moffat B, Vandlen R, Rosethal A, Hefti F (1995) Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373: 339–341
Yan Q, Matheson C, Lopez O (1995) In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature 373: 341–344
Oppenheim R, Houenou L, Johnson J, Lin L, Li L, Lo A, Newsome A, Prevette D, Wang S (1995) Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF Nature 373: 344–346
Fusco A, Grieco M, Santoro M, Berlingieri M, Pilotti S, Pierotti M, Della P, Vecchi G (1987) A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 328: 170–172
Grieco M, Santoro M, Berlingieri M, Melillo R, Donghi R, Bongarzone I, Pierotti M, Della Porta D, Fusco A, Vecchio G (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60: 557–563
Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I, Pasini B, Bocciardi R, Lerone M (1994) Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 367: 377–378
Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, Holder S (1994) Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367: 378–380
Donis-Keller H, Dou S, Chi D, Carlson K, Yoshima K, Lairmore T, HoweJ, Moley J, Goodfellow P, Wella S Jr. (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2: 851–856
Mulligan L, Kwok J, Healey C, Elsdon M, Eng C, Gardner E, Love D, Mole S, Moore J, Papi L (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458–460
Mulligan L, Eng C, Healey C, Clayton D, Kwok J, Gardner E, Ponder M, Frilling A, Jackson C, Lehnert H (1994) Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6: 70–74
Hofstra R, Landsvater R, Ceccherini I, Stulp R, Stelwagen T, Luo Y, Pasini B, Hoppener J, van Amstel H, Romeo G (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367: 375–376
Eng C, Smith D, Mulligan L, Nagai M, Healey C, Ponder M, Gardner E, Scheumann G, Jackson C, Tunnacliffe A (1994) Point mutation within the tyrosine kinase domain of the RET protooncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3: 237–241
Carlson K, Dou S, Chi D, Scavarda N, Toshima K, Jackson C, Wells SJ, Goodfellow P, Donis-Keller H (1994) Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia 2B. Proc Natl Acad Sci U S A 91: 1579–1583
Schiller M, Levy R, Shawa R, Abu-Dalu K, Gorenstein A, Katz S (1990) Familial Hirschsprung's disease - a report of 22 affected siblings in four families. J Pediatr Surg 25: 322–325
Stannard V, Fowler C, Roginson L, Besner G, Glick P, Allen J, Jewett T, Cooney D (1990) Familial Hirschsprung's disease: report of autosomal dominant and probable autosomal recessive X-linked kindreds. J Pediatr Surg 26: 591–594
Badner J, Sieber W Garver K, Chakravarti A (1990) A genetic study of Hirschsprung disease. Am J Genet 46: 568–580
Schimke R (1984) Genetic aspects of multiple endocrine neoplasia. Annu Rev Med 35: 25–31
Verdy M, Weber A, Roy C, Morin C, Cadotte M, Brochu P (1982) Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr 1: 603–607
Schimke R, Hartmann W Prout T, Rimoin D (1968) Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas. N Engl J Med 279: 1–7
Chong G, Beahrs O, Sizemore G, Woolner L (1975) Medullary carcinoma of the thyroid gland. Cancer 33: 695–704
Farndon J, Leight G, Dilley W Baylin S, Smallridge R, Harrison T, Wells SJ (1986) Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct entity. Br J Surg 73: 278–281
Pachnis V, Mankoo B, Costantini F (1993) Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 119: 1005–1017
Avantaggiato V, Dathan N, Grieco M, Fabien N, Lazzaro D, Fusco A, Simeone A, Santoro M (1994) Developmental expression of the RET protooncogene. Cell Growth Diff 5: 305–311
Tsuzuki T, Takahashi M, Asai N, Iwashita T, Matsuyama M, Asai J (1995) Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 10: 191–198
Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V (1994) Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor ret. Nature 367: 380–383
Sanchés M, Silos-Santiago I, Frisen J, He B, Lira S, Barbacid M (1996) Renal agenesis and the absence of enteric neurons in mice lacking GDNF Nature 382: 70–73
Pichel J, Shen L, Sheng H, Granholm A, Drago J, Grinberg A, Lee E, Huang S, Saarma M, Hoffer B (1996) Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382: 73–76
Moore M, Klein R, Farinas I, Sauer H, Armanini M, Phillips H, Reichardt L, Ryan A, Carver-Moore K, Rosenthal A (1996) Renal and neuronal abnormalities in mice lacking GDNF. Nature 382: 76–79
Kusafuka T, Puri P. Altered RET gene mRNA expression in Hirschsprung's disease. J Pediatr Surg: (in press)
Martucciello G, Favre A, Takahashi M, Jasonni V (1995) Immunohistochemical localization of RET protein in Hirschsprung's disease. J Pediatr Surg 30: 433–436
Tam P, Gould S, Martucciello G, Biddolph S, Takahashi M, Jasonni V (1996) Ret protein in the human fetal rectum. J Pediatr Surg 31: 568–571
Yntema C, Hammond W (1954) The origin of intrinsic ganglia of trunk viscera from vagal neural crest in the chick embryo. J Comp Neurol 101: 515–542
Le Douarin N, Teillet M (1973) The migration of neural crest cells to the wall of the digestive tract in avian embryo. J Embryol Exp Morph 30: 31–48
Durbec P, Larsson-Blomberg L, Schuchardt A, Costantini F, Pachnis V (1996) Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts. Development 122: 349–358
Lo L, Anderson D (1995) Postmigratory neural crest cells expressing c-RET display restriction developmental and proliferative capacities. Neuron 15: 527–539
Shah N, Marchionni M, Isaacs I, Stroobant P, Anderson D (1994) Glial growth factor restricts mammalian neural crest stem cells to a glial fate. Cell 77: 349–360
Stemple D, Anderson D (1992) Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell 71: 973–985
Martucciello G, Bicocchi M, Dodero P, Lerone M, Silengo Cirillo M, Puliti A, Gimelli G, Romeo G, Jasoni V (1992) Total colonic aganglionosis associated with interstitial deletion of the long arm of chromosome 10. Pediatr Surg Int 7: 308–310
Luo Y, Ceccherini I, Pasini B, Matera I, Bicocchi M, Barone V, Bocciardi R, Kaariainen H, Weber D, Devoto M (1993) Close linkage with the RET protooncogene and boundaries of deletion mutations in autosomal dominant Hirschsprung disease. Hum Mol Genet 2: 1803–1808
Fewtrell M, Tam P, Thomson A, Fitchett M, Currie J, Huson S, Mulligan L (1994) Hirschsprung's disease associated with deletion of chromosome 10 (g11.2q21.2): a further link with the neurocristopathies? J Med Genet
Lyonnet S, Bolino A, Pelet A, Abel L, Nihoul-Fekete C, Briard M, Mok-Siu V, Kaariainen H, Martucciello G, Lerone M (1993) A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10. Nat Genet 4: 346–350
Angrist M, Kauffman E, Slaugenhaupt S, Matise T, Puffenberger E, Washington S, Lipson A, Cass D, Reyna T, Weeks D (1993) A gene for Hirschsprung disease (megacolon) in the pericentromeric region of human chromosome 10. Nat Genet 4: 351–356
Chakravarti A (1996) Endothelin receptor-mediated signaling in Hirschsprung disease. Hum Mol Genet 5: 303–307
Angrist M, Bolk S, Thiel B, Puffenberger E, Hofstra R, Buys C, Cass D, Chakravarti A (1995) Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet 4: 821–830
Attie T, Pelet A, Edery P, Eng C, Mulligan L, Amiel J, Boutrand L, Beldjord C, Nihoul-Fekete C, Munnich A (1995) Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet 4: 1381–1386
Kusafuka T, Wang Y, Puri P (1996) Mutation analysis of the RET, the endothelin-B receptor and the endothelin-3 genes in sporadic patients with Hirschsprung's disease. J Pediatr Surg: (in press)
Hosoda K, Hammer RE, Richardson JA, Baynash AG, Cheung JC, Giaid A, Yanagisawa M (1994) Targeted and natural (piebaldlethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79: 1267–1276
Puffenberger EG, Hosoda K, Washington SS, Nakao K, deWit D, Yanagisawa M, Chakravarti A (1994) A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell 79: 1257–1266
Kusafuka T, Puri P (1997) Mutations of the endothelin-B receptor and endothelin-3 genes in Hirschsprung's disease. Pediatr Surg Int: (in press)
Baynash AG, Hosoda K, Giaid A, Richardson JA, Emoto N, Hammer RE, Yanagisawa M (1994) Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 79: 1277–1285
Lane P, Liu H (1984) Association of megacolon with a new dominant spotting gene (Dom) in the mouse. J Hered 75: 435–439
El-Halaby E, Coran A (1994) Hirschsprung's disease associated with Ondine's curse: report of three cases and review of the literature. J Pediatr Surg 29: 530–535
Barone V, Weber D, Luo Y, Brancolini V, Devoto M, Romeo G (1996) Exclusion of linkage between RET and neuronal intestinal dysplasia type B. Am J Med Genet 62: 195–198
Bolk S, Angrist M, Schwartz S, Silvestri J, Weeke-Mayer D, Chakravarti A (1996) Congenital central hypoventilation syndrome: Mutation analysis of the receptor tyrosine kinase RET. Am J Med Genet 63: 603–609
Pasini B, Borrello MG, Greco A, Bongarzone I, Luo Y, Mondellini P, Alberti L, Miranda C, Arighi E, Bocciardi R (1995) Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet 10: 35–40
Pierotti M, Santoro M, Jenkins R, Sozzi G, Bongarzone I, Grieco M, Monzini N, Miozzo M, Herrmann M, Fusco A (1992) Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Nad Acad Sci U S A 89: 1616–1620
Bongarzone I, Monzini N, Borrello M, Carcano C, Ferraresi G, Arighi E, Mondellini P, Della Porta G, Pierotti M (1993) Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Mol Cell Biol 13: 358–366
Sozzi G, Bongarzone I, Miozzo M, Berrello M, Blutti M, Pilotti S, Della Porta G, Pierotti M (1994) A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence, in papillary thyroid carcinoma. Genes Chromosom Cancer 9: 244–250
Bongarzone I, Butti M, Coronelli S, Borrello M, Santoro M, Mondellini P, Pilotti S, Fusco A, Della Porta G, Pierotti M (1994) Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinoma. Cancer Res 54: 2979–2985
Santoro M, Dathan N, Berlingieri M, Bongarzone I, Paulin C, Grieco M, Pierotti M, Vecchio G, Fusco A (1994) Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 9: 509–516
Minoletti F, Butti M, Coronelli S, Miozzo M, Sozzi G, Pilotti S, Tunnacliffe A, Pierotti M, Bongarzone I (1994) The two genes generating RET/PTC3 are localized in chromosomal band 10g11.2. Genes Chromosom Cancer 11: 51–57
Santoro M, Carlomagno F, Hay I, Herrmann M, Grieco M, Melillo R, Pierotti M, Bougarzone I, Della Porta G, Berger N (1992) Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89: 1517–1522
Santoro M, Sabino N, Ishizaka Y, Ushijima T, Carlomagno F, Cerrato A, Grieco M, Battaglia C, Martelli M, Paulin C (1993) Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. Br J Cancer 68: 460–464
Ito T, Seyama T, Iwamoto K, Hayashi T, Mizuno T, Tsuyama N, Dohi K, Nakamura N, Akiyama M (1993) In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res 53: 2940–2943
Ito T, Seyama T, Iwamoto K, Mizuno T, Tronko N, Komissarenko I, Cherstovoy E, Satow Y, Takeichi N, Dohi K (1994) Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet 344: 259
Simpson N, Kidd K, Goodfellow P, McDermid H, Myers S, Kidd J, Jackson C, Duncan A, Farrer L, Brasch K (1987) Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328: 528–530
Mathew C, Chin K, Easton D, Thorpe K, Carter C, Lion G, Fong S, Bridges C, Haak H, Nieuwenhuijzen Krusman A (1987) A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328: 527–528
Lairmore T, Howe J, Korte J, Dilley W, Aine I, Aine E, Wells S, Donis-Keller H (1991) Familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2B map to the same region of chromosome 10 as multiple endocrine neoplasia type 2A. Genomics 9: 181–192
Carson N, Wu J, Jackson C, Kidd K, Simpson N (1990) The mutation for medullary thyroid carcinoma with parathyroid tumours (MTC with PTs) is closely linked to the centromeric region of chromosome 10. Am J Hum Genet 47: 946–951
Gardner E, Papi L, Easton D, Cummings T, Jackson C, Kaplan M, Love D, Mole S, Moore J, Mulligan L (1993) Genetic linkage studies map the multiple endocrine neoplasia type 21oci to a small interval on chromosome 10g11.2. Hum Mol Genet 2: 241–246
Mole S, Mulligan L, Healey C, Ponder B, Tunnacliffe A (1993) Localisation of the gene for multiple endocrine neoplasia type 2A to a 480 kb region in chromosome band 10g11.2. Hum Mol Genet 2: 247–252
Mulligan I, Eng C, Attie T, Lyonnet S, Marsh D, Hyland V, Robinson B, Frilling A, Verellen-Dumoulin C, Safar A (1994) Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 3: 2163–2167
Mulligan L, Marsh D, Robinson B, Schuffenecker I, Zedenius J, Lips C, Gagel R, Takai S, Noll W Fink M (1995) Genotypephenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238: 343–346
Schuffenecker I, Billaud M, Calender A, Chambe B, Ginet N, Calmettes C, Modigliani E, Lenoir G (1994) RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 3: 1939–1943
Eng C, Smith D, Mulligan L, Healey C, Zvelebil M, Stonehouse T, Ponder M, Jackson C, Waterfield M, Ponder B (1995) A novel point mutation in the tyrosine kinase domain of the RET protooncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10: 509–513
Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M (1995) RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10: 2415–2419
Hanks S, Quinn A, Hunter T (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domain. Science 241: 42–52
Eng C, Mulligan L, Smith D, Healey C, Frilling A, Raue F, Neumann H, Pfragner R, Behmel A, Lorenzo M (1995) Mutation of the RET proto-oncogene in sporadic medullary thyroid carcinoma. Genes Chromosom Cancer 12: 209–212
Tong Q, Li Y, Smanik P, Fithian L, Xing S, Mazzaferri E, Jhiang S (1995) Characterization of the promoter region and oligomerization domain of H4 (D10S170), a gene frequently rearranged with the ret proto-oncogene. Oncogene 10: 1781–1787
Asai N, Iwashita T, Matsuyama M, Takahashi M (1995) Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15: 1613–1619
Borrello M, Smith D, Pasini B, Bongarzone I, Greco A, Lorenzo M, Arighi E, Miranda C, Eng C, Alberti L (1995) RET activation by germline MEN 2A and MEN 2B mutations. Oncogene 11: 2419–2427
Santoro M, Carlomango F, Romano A, Bottaro D, Dathan N, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus M (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 267: 381–383
Songyang Z, Carraway KI, Eck M, Harrison S, Feldman R, Mohammadi M, Schlessinger J, Hubbard S, Smith D, Eng C (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373: 536–539
Borst M, VanCamp J, Peacock M, Decker R (1995) Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Surgery 117: 386–391
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kusafuka, T., Puri, P. TheRET proto-oncogene: A challenge to our understanding of disease pathogenesis. Pediatr Surg Int 12, 11–18 (1997). https://doi.org/10.1007/BF01194794
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01194794